HUM-MOLGEN events: Formulation Strategies for Biopharmaceuticals

HUM-MOLGEN -> Events -> Meetings and Conferences

Formulation Strategies for Biopharmaceuticals

November 08, 2000

IBC USA Conferences, Paradise Point Resort, San Diego, CA
2001-03-06

One of the more important, but possibly the least regarded, aspects of drug development is formulation design. Challenges associated with biopharmaceutical formulation are complex, and scientists performing formulation development for macromolecules must have full knowledge of the complications that these molecules present and strategies for overcoming formulation hurdles.

IBC’s Formulation Strategies for Biopharmaceuticals conference will provide practical, applied requirements for successful commercialization of your biopharmaceutical product. This event will focus on the critical aspects and differences of physicochemical properties of macromolecules and specific selection of compatible excipients to impart desired stability on the product. Rational designs of preformulations, liquid or lyophilized formulations, and requirements for viral and non-viral gene vector formulations will be discussed. Development and application of analytical methodology concerning stability indicating assays will be described to support critical handling of biopharmaceuticals to the market. Regulatory compliance for global registration, including ICH requirements, will also be detailed.

This year’s program features a compelling pre-conference symposium on Non-Traditional Approaches to Biotechnology Drug Delivery. This half-day symposium will provide case studies and new data from Schering-Plough Corporation, Zycos, Nobex Corporation, Genzyme Corporation, and Intellivax International Inc. Come hear how companies are approaching formulation and delivery of biopharmaceuticals in novel ways!

Organized by:

IBC USA Conferences

Invited Speakers:

Ben Isaac, PhD, President, Formatech
Douglas Kline, PhD, Section Leader, Sterile Product Formulation, Schering-Plough Corporation
Mike A. Tyo, PhD, Head of Manufacturing & Process Development, Zycos
Rick Soltero, PhD, Director, Pharmaceutical Development, Nobex Corporation
Peter Hoffmann, PhD, Vice President, New Technology Development, Genzyme

Deadline for Abstracts:

November 1, 2001

Registration:

www.ibcusa.com/2624

E-mail:

janderson@ibcusa.com

Posted by:

Julie Anderson

Host:

209.6.93.46